A phase II study of hypofractionated proton therapy for prostate cancer

References

• Hausterman K, Fowler JF. A comment on proliferation rates in human prostate cancer. Int J Radiat Oncol Biol Phys 2000;48:303.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095–101.
   PubMed Web of Science ®Google Scholar
• Fowler J. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003; 56:1093–104.
   PubMed Web of Science ®Google Scholar
• Fowler J, King CR. Don’t squeeze hypofractionated schedules into too-short overall times. Int J Radiat Oncol Biol Phys 2009;75:323–5.
   PubMed Web of Science ®Google Scholar
• Slater JD, Rossi CJ, Jr., Yonemoto LT, Bush DA, Jabola BR, Levy RP, . Proton therapy for prostate cancer: The initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004;59:348–52.
   PubMed Web of Science ®Google Scholar
• Perez CA, Michalski J, Mansur D, Lockett MA. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. Cancer J 2004;10:349–56.
   PubMed Web of Science ®Google Scholar
• Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: Tolerable levels in altered fractionation schedules. Radiother Oncol 2003;69:161–8.
   PubMed Web of Science ®Google Scholar
• Dorr W, Hamilton CS, Boyd T, Reed B, Denham JW. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002; 52:911–7.
   PubMed Web of Science ®Google Scholar
• Yoon M, Kim D, Shin DH, Park SY, Lee SB, Kim DY, . Inter- and intrafractional movement-induced dose reduction of prostate target volume in proton beam treatment. Int J Radiat Oncol Biol Phys 2008;71:1091–102.
   PubMed Web of Science ®Google Scholar
• Simon R, Wittes R, Ellenberg S. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375.
   PubMedGoogle Scholar
• Barry MJ, Fowler FJ, Jr., O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, . The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57; discussion 64.
   PubMed Web of Science ®Google Scholar
• LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995;31:1049–91.
   PubMedGoogle Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 2003;41:582–92.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, . A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11–8.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari MG, . Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1013–21.
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68:1424–30.
   PubMed Web of Science ®Google Scholar
• Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, . Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 69:1084–9.
   PubMed Web of Science ®Google Scholar
• Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099–105.
   PubMed Web of Science ®Google Scholar
• King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti Jr JC. Stereotactic body radiotherapy for localized prostate cancer: Interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73: 1043–8.
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, . Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097–105.
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, . Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67–74.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, . Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar